Clinical Spectrum and Treatment Outcomes of Pediatric Hodgkin Lymphoma: A Retrospective Study from a Resource-Limited Setting

Nazia  Rafique; Muhammad Hassan Laique; Nuzhat  Yasmeen; Sughra  Zulfiqar; Ruqayya  Manzoor; Hijab  Shaheen

doi:10.51253/pafmj.v76iSUPPL-8.13844

Authors

Nazia Rafique Department of Pediatric Oncology, Pakistan Institute of Medical Sciences, Islamabad Pakistan
Muhammad Hassan Laique Department of Pediatric Oncology, Pakistan Institute of Medical Sciences, Islamabad Pakistan
Nuzhat Yasmeen Department of Pediatric Oncology, Pakistan Institute of Medical Sciences, Islamabad Pakistan
Sughra Zulfiqar Department of Pediatric, Watim Medical College Rawalpindi Paksitan
Ruqayya Manzoor Department of Pediatric Oncology, Pakistan Institute of Medical Sciences, Islamabad Pakistan
Hijab Shaheen Department of Pediatric Oncology, Pakistan Institute of Medical Sciences, Islamabad Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-8.13844

Keywords:

B symptoms, Classical Hodgkin Lymphoma, Delayed Diagnosis, Epidemiology, Mixed Cellularity, Pediatric Hodgkin Lymphoma, Resource Limited Setting, Survival Outcomes

Abstract

Objective: To evaluate the epidemiological, clinicopathological features, and treatment outcomes of Pediatric Hodgkin Lymphoma (HL) in low- and middle-income countries (LMICs) over 15 years.

Study Design: Retrospective Analytical Study

Place and Duration of Study: Pediatric Hematology and Oncology Center, Pakistan Institute of Medical Sciences (PIMS) in Islamabad, Pakistan, from Jan 2007 to Dec 2021.

Methodology: The study analyzed 155 pediatric HL cases treated at study setting over a period of 15 years retrospectively. Cases were reviewed for age, gender distribution, clinical presentation, histological subtypes, disease staging, treatment response, and survival outcomes. Findings were compared with national and international literature.

Results: The mean age at diagnosis was 7.4 years, with 56.1% of cases between 6–10 years and a male-to-female ratio of 4:1. Classical HL (96.1%) was predominant, with mixed cellularity (63.2%) as the most common subtype. Advanced-stage disease (Stage III–IV) was observed in 75.0% of patients, and B symptoms were present in 63.2%. Despite late presentation, event-free survival (EFS) and overall survival (OS) were 89.0% and 93.5%, respectively. The relapse rate was 7.1%, with limited salvage success due to a lack of advanced therapeutic modalities.

Conclusion: This study highlights significant diagnostic and systemic delays contributing to advanced-stage presentation in pediatric HL. Despite resource limitations, survival outcomes were comparable to international standards, reflecting effective treatment protocols. Measures are needed to work on early detection, referral systems, and oncology infrastructure to further improve paediatric HL outcomes in Pakistan and similar poor countries.

Downloads

Download data is not yet available.

References

1. Ward E, DeSantis C, Robbins A, Kohler B, Jamal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64(2): 83-103. https://doi.org/10.3322/caac.21219

2. Heneghan MB, Belsky JA, Milgrom SA, Forlenza CJ. The pediatric approach to Hodgkin lymphoma. Semin Hematol 2024; 61(4): 245-252.

3. https://doi.org/10.1053/j.seminhematol.2024.05.003

4. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 2018; 68(2): 116-132.

https://doi.org/10.3322/caac.21438

5. Polyatskin IL, Artemyeva AS, Krivolapov YA. [Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition): lymphoid tumors]. Arkh Patol 2019; 81(3): 59-65. https://doi:10.17116/patol20198103159.

6. Choi JK, Quintanilla-Martinez L. Pediatric lymphomas: overview and diagnostic challenges. Virchow’s Arch 2025; 486(1): 81-100. https://doi.org/10.1007/s00428-024-03980-9

7. Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, et al. Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 2021; 68: e28562.

https://doi.org/10.1002/pbc.28562

8. Cotache-Condor C, Rice HE, Schroeder K, Staton C, Majaliwa E, Tang S, et al. Delays in cancer care for children in low- and middle-income countries: development of a composite vulnerability index. The Lancet Global Health. 2023; 11(4): e505-e515. https://doi.org/10.1016/S2214-109X(23)00053-0

9. Moleti ML, Testi AM, Al-Hadad S, Al-Jadiry MF, Foà R. Pediatric Hodgkin Lymphoma in Low-and Middle-Income Countries (LMICs). A Narrative Review. Mediterr J Hematol Infect Dis 2024; 16(1): e2024078.

https://doi.org/10.4084/MJHID.2024.078

10. Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma. N Engl J Med 2022; 387(18): 1649-1660.

https://doi.org/10.1056/NEJMoa2206660

11. Bechara E, Eid T, El‐Dhuwaib A, Tamim H, Noun D, Borghol R, et al. Outcome and Challenges in the Treatment of Pediatric Hodgkin Lymphoma With Euronet‐PHL‐C1 Protocol: Experience From a Resource‐Limited Country. Cancer Med 2025; 14(15): e71095. https://doi.org/10.1002/cam4.71095

12. Mousavi SE, Najafi M, Aslani A, Ghasemi H, Yekta Z, Nejadghaderi SA. Population-based analysis of twenty-year incidence trends of pediatric Hodgkin lymphoma in the United States. Sci Rep 2025; 15(1): 22634.

https://doi.org/10.1038/s41598-025-07472-x

13. Ashraf MS, Naz F, Yakoob MY. Characteristics and survival outcomes of children with Hodgkin lymphoma treated primarily with chemotherapy. J Pediatr Hematol / Oncol 2019; 41(6): 452-456.

https://doi.org/0.1097/MPH.0000000000001496

14. Sherief LM, Elsafy UR, Abdelkhalek ER, Kamal NM, Elbehedy R, Hassan TH, et al. Hodgkin lymphoma in childhood: clinicopathological features and therapy outcome at 2 centers from a developing country. Med 2015; 94(15): e670.

https://doi.org/10.1097/MD.0000000000000670

15. Linabery AM, Erhardt EB, Richardson MR, Ambinder RF, Friedman DL, Glaser Slet al. Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. Int J Cancer 2015; 137(9): 2163-2174.

https://doi.org/10.1002/ijc.29589

16. Rehman P, Wali RM. Response Assessment And Outcomes In Pediatric B-Cell Non-Hodgkin Lymphoma: Our Experience At Shaukat Khanum Memorial Cancer Hospital And Research Centre. Pak Armed Forces Med J 2020; 70(5): 1402-1407.

https://pafmj.org/PAFMJ/article/view/5573

17. Bhurani D, Nair R, Rajappa S, Rao SA, Sridharan N, Boya RR, et al. Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India. Front Oncol 2022; 11: 799948.

https://doi.org/10.3389/fonc.2021.799948

18. Kaseb H, Babiker HM. Hodgkin Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. [updated 2023 Jun 26; cited 2026 Jul 09]. Available from:

https://www.ncbi.nlm.nih.gov/books/NBK499969/

19. Riaz S, Khan S, Badar F. Pediatric Hodgkin’s Lymphoma: 5-Year Experience at a Single Center in Pakistan.

https://doi.org/10.1182/blood.V124.21.5455.5455

20. Englund A, Glimelius I, Rostgaard K, Smedby KE, Eloranta S, Molin D, et al. Hodgkin lymphoma in children, adolescents and young adults–a comparative study of clinical presentation and treatment outcome. Acta Oncologica 2018; 57(2): 276-282.

https://doi.org/10.1080/0284186X.2017.1355563

21. Geel JA, Hramyka A, Du Plessis J, Goga Y, Van Zyl A, et al. Machine learning to predict interim response in pediatric classical Hodgkin lymphoma using affordable blood tests. JCO Global Oncol 2024; 10: e2300435.